Premium
Circulating levels and clinical significance of soluble CD86 in myeloma patients
Author(s) -
Hock B. D.,
Drayson M.,
Patton W. N.,
Taylor K.,
Kerr L.,
McKenzie J. L.
Publication year - 2006
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2006.05983.x
Subject(s) - medicine , multiple myeloma , cyclophosphamide , melphalan , gastroenterology , carmustine , prednisolone , univariate analysis , chemotherapy , multivariate analysis , oncology
Summary Circulating soluble CD86 (sCD86) levels are elevated in a number of leukaemias and are an independent prognostic factor in acute myeloid leukaemia. We investigated the clinical significance of circulating sCD86 in 299 patients from the UK Medical Research Council myeloma VIth trial, where patients received ABCM [adriamycin, carmustine (BCNU), cyclophosphamide, melphalan] either alone or with prednisolone (ABCM + P). Serum levels of sCD86 were significantly elevated ( P = 0·0001) in myeloma patients and using the median normal donor level (0·621 ng/ml) as a cut‐off point, 70% of patients had elevated levels (range = 0·015–15·87 ng/ml, median = 1·1 ng/ml). In univariate analysis elevated sCD86 levels were associated with significantly shorter ( P < 0·001) survival (median = 22 vs. 51 months) and event‐free survival (median = 14 vs. 31 months) in ABCM + P but not ABCM patients. Multivariate analysis demonstrated that sCD86 was a significant, independent prognostic marker of both overall [risk ratio (RR) = 2·04, P = 0·0006] and event‐free (RR = 1·95, P = 0·0004) survival in ABCM + P patients. In conclusion, this study demonstrated that sCD86 levels are a significant independent prognostic marker in at least some myeloma treatment groups and its biological role and prognostic value should be further investigated.